Financial Survey: Rocket Pharmaceuticals (NASDAQ:RCKT) & Pharma Mar (OTCMKTS:PHMMF)

Rocket Pharmaceuticals (NASDAQ:RCKT) and Pharma Mar (OTCMKTS:PHMMF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Pharma Mar shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Rocket Pharmaceuticals and Pharma Mar’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Pharma Mar	N/A	N/A	N/A

Volatility & Risk

Rocket Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Rocket Pharmaceuticals and Pharma Mar, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3	3	5	1	2.33
Pharma Mar	0	1	1	1	3.00

Rocket Pharmaceuticals presently has a consensus price target of $8.88, indicating a potential upside of 173.08%. Given Rocket Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Rocket Pharmaceuticals is more favorable than Pharma Mar.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Pharma Mar”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12 million	($1.87)	-1.74
Pharma Mar	$250.42 million	5.71	$84.84 million	N/A	N/A

Pharma Mar has higher revenue and earnings than Rocket Pharmaceuticals.

Summary

Pharma Mar beats Rocket Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.